Michal Marszal is a Portfolio Manager with Equities – Global Healthcare at CIBC Asset Management.
He is responsible for research coverage and stock selection within the global healthcare sector.
Prior to joining CIBC in 2017, Mr. Marszal was a consultant in healthcare equity research for Caisse de dépôt et placement du Québec. Previously, he was a senior analyst focusing on healthcare therapeutics at Lombard Odier Investment Managers. Mr. Marszal began his investment career as an analyst covering medical technology, and subsequently biotechnology companies at Sectoral Asset Management.
Mr. Marszal holds a Doctor of Medicine and Master of Surgery degree from McGill University. Upon graduating from medical school, he joined the Neurological Surgery Residency training program at Stanford University Medical Center as a resident physician. Mr. Marszal also holds an MBA degree in Finance from McGill University and a Bachelor of Arts degree in Molecular Biology from Bard College. He is a CFA charterholder and member of the CFA Society of Toronto.
Most of the sector maintains demand across economic cycles, PM says.
Certain segments expected to perform better than others this year.
Valuations are looking more attractive for those who can handle the risk.
Higher input costs are shrinking margins.
Where the sector goes from here.
Pfizer and Moderna continue to come out on top.
Understanding innovation in the sector helps reveal top stocks.